Last reviewed · How we verify

Propofol / Remifentanil

University General Hospital of Patras · FDA-approved active Small molecule

Propofol is a GABA-A receptor agonist that induces sedation/anesthesia, while remifentanil is a mu-opioid receptor agonist that provides analgesia and enhances sedation.

Propofol is a GABA-A receptor agonist that induces sedation/anesthesia, while remifentanil is a mu-opioid receptor agonist that provides analgesia and enhances sedation. Used for Induction and maintenance of general anesthesia, Sedation in mechanically ventilated patients in intensive care.

At a glance

Generic namePropofol / Remifentanil
SponsorUniversity General Hospital of Patras
Drug classSedative-hypnotic (propofol) and opioid analgesic (remifentanil)
TargetGABA-A receptor (propofol); mu-opioid receptor (remifentanil)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Propofol enhances inhibitory GABAergic neurotransmission in the central nervous system, producing rapid onset sedation and hypnosis. Remifentanil binds to mu-opioid receptors to provide potent analgesia and synergistic sedative effects. Together, this combination is used for total intravenous anesthesia (TIVA), where the opioid reduces the propofol dose requirement while improving pain control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: